Literature DB >> 21323799

Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US).

A A Sharathkumar1, J M Soucie, B Trawinski, A Greist, A D Shapiro.   

Abstract

The primary objective of the study was to examine the prevalence of cardiovascular disease (CVD) events and their known risk factors among persons with haemophilia (PWH). This cross-sectional study, covering a 5-year period, included PWH aged ≥35 years who were cared for at a single haemophilia treatment centre in the United States. Medical records were extensively reviewed to collect the information about CVD events and their risk factors such as obesity, hypertension, diabetes, hypercholesterolemia and smoking. Prevalence rates were compared with national population estimates and associations between risk factors and CVD events were examined using logistic regression. The study cohort comprised 185 PWH (102 haemophilia A and 83 haemophilia B). Lifetime prevalence of a CVD event was 19.5% (36/185, 95% confidence interval [CI] 13.8-25.2%). CVD mortality was 5.4% (10/185, 95% CI 2.7-8.1). Compared with US non-Hispanic White males (NHWH), PWH had about twice the prevalence of coronary artery disease, stroke and myocardial infarction. The prevalence of CVD risk factors for PWH was similar to that for US NHWM with 39.5% of PWH exposed to two or more of these risk factors. Both hypertension and smoking were associated significantly with CVD events, with odds ratios of 4.9 and 6.3, respectively. In conclusion, this study revealed that both CVD events and its risk factors were at least equally prevalent among PWH and might have been even higher than among the US NHWM in the United States. Therefore, it is imperative to implement strategies for CVD prevention among PWH.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21323799     DOI: 10.1111/j.1365-2516.2010.02463.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

Review 1.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

2.  Tailoring care to haemophilia patients' needs: which specialty and when?

Authors:  Massimo Morfini; Gary Benson; Victor Jiménez-Yuste; Rolf Ljung; Pier Mannuccio Mannucci; Gianluigi Pasta; Eduardo Remor; Silva Zupančić Šalek
Journal:  Blood Transfus       Date:  2015-05-20       Impact factor: 3.443

3.  Prevalence and risk factors for hypertension in hemophilia.

Authors:  Annette von Drygalski; Nicholas A Kolaitis; Ricki Bettencourt; Jaclyn Bergstrom; R Kruse-Jarres; Doris V Quon; Christina Wassel; Ming C Li; Jill Waalen; Darlene J Elias; Laurent O Mosnier; Matthew Allison
Journal:  Hypertension       Date:  2013-04-29       Impact factor: 10.190

4.  High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature.

Authors:  Ming Y Lim; Guo Wei; Angela P Presson; Paul Bray; George M Rodgers
Journal:  Blood Coagul Fibrinolysis       Date:  2020-12       Impact factor: 1.276

Review 5.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644

Review 6.  Comorbidities of cardiovascular disease and cancer in hemophilia patients.

Authors:  Jiaan-Der Wang
Journal:  Thromb J       Date:  2016-10-04

7.  Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Authors:  Chatree Chai-Adisaksopha; Mark W Skinner; Randall Curtis; Neil Frick; Michael B Nichol; Declan Noone; Brian O'Mahony; David Page; Jeffrey Stonebraker; Lehana Thabane; Mark Crowther; Alfonso Iorio
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

8.  Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention.

Authors:  Kathryn E Dane; John P Lindsley; Michael B Streiff; Alison R Moliterno; Mian K Khalid; Satish Shanbhag
Journal:  Res Pract Thromb Haemost       Date:  2019-04-09

Review 9.  Mortality in congenital hemophilia A - a systematic literature review.

Authors:  Charles R M Hay; Francis Nissen; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

10.  The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study.

Authors:  Richard F W Barnes; Thomas J Cramer; Afrah S Sait; Rebecca Kruse-Jarres; Doris V K Quon; Annette von Drygalski
Journal:  Int J Hypertens       Date:  2016-11-14       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.